PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test PanelLin Yang(Mayo Clinic), Jann N. Sarkaria(Mayo Clinic)Clinical Cancer ResearchJune 15, 200810.1158/1078-0432.ccr-07-4152Cited by 60SaveCiteExport RISWatch citationsRelated PapersInduction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts|Neuro-Oncology|2008|386<i>In Vivo</i> Efficacy of Tesevatinib in <i>EGFR</i> -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling|Molecular Cancer Therapeutics|2021|13